Twist Bioscience Corporat... (TWST)
36.81
-1.64 (-4.27%)
At close: Apr 17, 2025, 3:59 PM
37.87
2.88%
After-hours: Apr 17, 2025, 06:50 PM EDT
Twist Bioscience Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antibody Discovery Revenue | 5.3M | 5.1M | 4.7M | 5.23M | 3.39M | 4.58M | 7.03M | 8.17M | 6.53M | 6.24M | 6.59M | 4.81M | 4.1M | 3.14M | 3.22M | 1.51M | 1.2M | 1M | 1.1M | 1.24M | 1.31M | 1.21M | 1.26M | 810K |
| Antibody Discovery Revenue Growth | +3.86% | +8.53% | -10.05% | +54.30% | -26.05% | -34.89% | -13.92% | +25.17% | +4.58% | -5.24% | +36.86% | +17.50% | +30.45% | -2.58% | +113.44% | +26.04% | +19.32% | -8.81% | -11.35% | -5.48% | +8.24% | -3.34% | +55.06% | n/a |
| Dna And Biopharma Libraries Revenue | 3.62M | 3.85M | 3.53M | 2.94M | 2.66M | 2.88M | 2.83M | 1.84M | 1.5M | 1.42M | 1.97M | 1.26M | 21.45M | 18.7M | 16.95M | 8.87M | 8.64M | 9.6M | 9.12M | 7.84M | 7.86M | 6.24M | 6.1M | 6.51M |
| Dna And Biopharma Libraries Revenue Growth | -6.06% | +8.98% | +20.14% | +10.53% | -7.67% | +1.91% | +53.92% | +22.48% | +5.41% | -27.71% | +55.99% | -94.12% | +14.71% | +10.30% | +91.02% | +2.76% | -10.08% | +5.35% | +16.33% | -0.33% | +25.95% | +2.36% | -6.34% | n/a |
| Ngs Tools Revenue | 45.54M | 43.4M | 40.77M | 39.42M | 37.11M | 33.24M | 28.99M | 24.36M | 29.19M | 27.79M | 23.1M | 19.23M | 2.67M | 2.02M | 1.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ngs Tools Revenue Growth | +4.92% | +6.44% | +3.44% | +6.23% | +11.62% | +14.65% | +19.01% | -16.54% | +5.03% | +20.29% | +20.13% | +619.72% | +32.47% | +9.56% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Oligo Pools Revenue | 4.61M | 4.17M | 3.94M | 4.19M | 3.74M | 3.73M | 3.31M | 3.7M | 3.67M | 3.26M | 2.31M | 3.19M | 9.74M | 11.16M | 9.19M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Oligo Pools Revenue Growth | +10.68% | +5.74% | -5.94% | +12.01% | +0.13% | +12.67% | -10.38% | +0.82% | +12.58% | +41.20% | -27.60% | -67.26% | -12.79% | +21.49% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Synthetic Genes Revenue | 25.65M | 24.95M | 22.36M | 19.73M | 20.05M | 19.3M | 18.01M | 16.18M | 16.42M | 17.4M | 14.16M | 13.53M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Synthetic Genes Revenue Growth | +2.81% | +11.59% | +13.33% | -1.63% | +3.89% | +7.17% | +11.35% | -1.50% | -5.63% | +22.86% | +4.72% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 |
|---|---|---|---|---|---|---|
| Americas Revenue | 193.88M | 151.26M | 122.47M | 77.91M | 1.08M | 2.76M |
| Americas Revenue Growth | +28.18% | +23.51% | +57.20% | +7087.18% | -60.74% | n/a |
| Asia Pacific Revenue | 26.52M | 22.46M | 19.01M | 10.3M | 5.12M | 14.69M |
| Asia Pacific Revenue Growth | +18.11% | +18.11% | +84.60% | +101.37% | -65.19% | n/a |
| Emea Revenue | 92.57M | 71.39M | 62.08M | n/a | 25.82M | n/a |
| Emea Revenue Growth | +29.67% | +15.00% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 56.18M | 53.14M | 56.79M | 55.62M | 52.84M | 47.39M | 46.06M | 53.97M | 42.32M | 54.16M | 53.69M | 54M | 51.1M | 38.24M | 34.48M | 34.39M | 28.79M | 27.18M | 22.49M | 27.19M | 26.41M | 24.42M | 21.32M | 19.12M | 15.26M | 12.95M | 11.26M | 9.98M | 9.26M | 8.41M | 5.92M |
| Selling, General, and Administrative Revenue Growth | +5.71% | -6.43% | +2.11% | +5.26% | +11.50% | +2.90% | -14.65% | +27.50% | -21.85% | +0.87% | -0.56% | +5.68% | +33.61% | +10.92% | +0.26% | +19.44% | +5.91% | +20.89% | -17.30% | +2.97% | +8.12% | +14.55% | +11.48% | +25.33% | +17.80% | +15.08% | +12.81% | +7.72% | +10.16% | +42.07% | n/a |
| Research and Development Revenue | 21.31M | 21.13M | 22.47M | 24.15M | 23.1M | 23.75M | 24.53M | 27.38M | 31.24M | 29.61M | 36.84M | 31.23M | 22.63M | 19.44M | 19.84M | 15.79M | 14M | 11.64M | 10.44M | 10.63M | 10.3M | 10.5M | 9.01M | 8.91M | 7.27M | 6.07M | 5.27M | 4.71M | 4.3M | 4.85M | 5.28M |
| Research and Development Revenue Growth | +0.82% | -5.94% | -6.96% | +4.55% | -2.72% | -3.19% | -10.41% | -12.36% | +5.53% | -19.64% | +17.96% | +38.01% | +16.39% | -1.99% | +25.63% | +12.79% | +20.32% | +11.41% | -1.74% | +3.22% | -1.90% | +16.53% | +1.12% | +22.47% | +19.92% | +15.13% | +11.82% | +9.48% | -11.30% | -8.07% | n/a |